Patented transdermal drug candidate from Vascarta may offer a convenient & cost-effective way to treat sickle cell disease

Vascarta’s transdermal drug candidate may offer a convenient, cost-effective solution for treating sickle cell disease. With improved delivery and potential for at-home use, the innovation addresses key challenges in managing this chronic condition. Read the full article